# Anfibatide Treatment in STEMI Patients

Study · id `cardio:ct-nct02495012` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02495012](<https://clinicaltrials.gov/study/NCT02495012>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02495012

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 240 participants.

## Technical summary

Registry record NCT02495012. Randomized; double masking; primary purpose treatment. Start 2015-08 (registry gives no type); primary completion 2016-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 240 participants (planned count; ClinicalTrials.gov record NCT02495012, source copy `cardio:ctgov-nct02495012-2015-07-13`, retrieved 2026-10-26)
- Start date: 2015-08 (registry gives no type) (ClinicalTrials.gov record NCT02495012, source copy `cardio:ctgov-nct02495012-2015-07-13`, retrieved 2026-10-26)
- Primary completion: 2016-03 (anticipated) (ClinicalTrials.gov record NCT02495012, source copy `cardio:ctgov-nct02495012-2015-07-13`, retrieved 2026-10-26)
- Completion: 2016-05 (anticipated) (ClinicalTrials.gov record NCT02495012, source copy `cardio:ctgov-nct02495012-2015-07-13`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT02495012, source copy `cardio:ctgov-nct02495012-2015-07-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02495012-2015-07-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Anfibatide Treatment in STEMI Patients
- Condition: ST Segment Elevation Myocardial Infarction
- Intervention (Drug): placebo
- Intervention (Drug): Anfibatide
- Lead sponsor: Lee's Pharmaceutical Limited
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry lists this organization as the lead sponsor: Lee's Pharmaceutical Limited (`cardio:org-lee-s-pharmaceutical-limited`)

## Provenance

Content hash: 0a085365d211a056572d3b6b6193fab9063f1cb8a86ceda1421194cf198c2e26
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
